About Valsartan API
Therapeutic CategoryCardiovascular
CAS Number
137862-53-4
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, CEP Submitted, Brazil DMF, EUDMF, Canada DMF, Japan DMF, Korea DMF, China DMF
Mechanism of Action
Valsartan blocks the actions of angiotensin II, which include constricting blood vessels and activating aldosterone, to reduce blood pressure.[7]The drug binds to angiotensin type I receptors (AT1), working as an antagonist. This mechanism of action is different than that of the ACE inhibitor drugs, which block the conversion of angiotensin I to angiotensin II. As valsartan acts at the receptor, it can provide more complete angiotensin II antagonism since angiotensin II is generated by other enzymes as well as ACE. Also, valsartan does not affect the metabolism of bradykinin like ACE inhibitors do
Indication
Diovan is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions
- Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure
- Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction
Related APIs
Amlodipine Besylate
Cardiovascular
Apixaban
Cardiovascular
Bempedoic Acid
Cardiovascular
Clopidogrel Bisulfate (Form 1)
Cardiovascular
Clopidogrel Bisulfate (Form 2)
Cardiovascular
Dabigatran Etexilate Mesylate
Cardiovascular
Doxazosin Mesylate
Cardiovascular
Ezetimibe
Cardiovascular
Fondaparinux Sodium
Cardiovascular
Lacidipine
Cardiovascular
Losartan Potassium
Cardiovascular
Mavacamten
Cardiovascular
Metoprolol Succinate
Cardiovascular
Ramipril
Cardiovascular
Rivaroxaban
Cardiovascular
Tafamidis Free Acid
Cardiovascular
Tafamidis Meglumine
Cardiovascular
Ticagrelor
Cardiovascular
Treprostinil
Cardiovascular
Treprostinil Olamine
Cardiovascular
Valsartan
Cardiovascular
Atorvastatin Calcium (Amorphous And Form P)
Cardiovascular
Sacubitril-Valsartan
Cardiovascular
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related Resources
FAQs
High blood pressure, heart failure, and diabetic kidney disease.
-
Congestive heart failure - 40 mg orally twice a day(Maintenance dose: 80 to 160 mg twice a day). Hypertension - 80 to 160 mg orally once a day (Maintenance dose: 80 to 320 mg orally once a day).
-
We offer Essentially amorphous form
-
Meet with our product experts in one-on-one virtual sessions at https://api.drreddys.com/meet-api-experts or Write to us at [email protected].
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.